Omitting surgery for early breast cancer showing clinical complete response to primary systemic therapy
Open Access
- 7 May 2020
- journal article
- review article
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 50 (6), 629-634
- https://doi.org/10.1093/jjco/hyaa055
Abstract
Breast cancer is highly sensitive to systemic therapy. High probability of pathological complete response suggests a clinical question that omitting surgery is an effective alternative to surgery in breast cancer showing clinical complete response to primary systemic therapy. However, the validity of omitting surgery for early breast cancer after primary systemic therapy has not been sufficiently established; thus, even if pathological complete response is expected in patients showing clinical complete response, excision of the primary tumor site remains the standard treatment of breast cancer. Inappropriate omitting surgery increases the incidence of local recurrence, which can be the risk of a subsequent distant metastasis and reduced overall survival. To achieve acceptable local control rate, omitting surgery should be investigated in patients with early breast cancer where a high percentage of pathological complete response, a high concordance rate between clinical complete response and pathological complete response and an acceptable local control rate are expected. This review presents concept and ongoing clinical trials for omitting surgery for patients with breast cancer showing clinical complete response to primary systemic therapy.Keywords
Funding Information
- National Cancer Center Research and Development Fund (29-A-3)
- Ministry of Health, Labour and Welfare (19ck0106307h0003)
- Japan Agency for Medical Research and Development
This publication has 42 references indexed in Scilit:
- Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)Annals of Oncology, 2013
- Meta-Analysis of Magnetic Resonance Imaging in Detecting Residual Breast Cancer After Neoadjuvant TherapyJNCI Journal of the National Cancer Institute, 2013
- Analysis of complete response by MRI following neoadjuvant chemotherapy predicts pathological tumor responses differently for molecular subtypes of breast cancerOncology Letters, 2012
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialThe Lancet Oncology, 2012
- Is Radiotherapy an Option for Early Breast Cancers With Complete Clinical Response After Neoadjuvant Chemotherapy?International Journal of Radiation Oncology*Biology*Physics, 2011
- The safety of breast‐conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapyCancer, 2006
- Sexual Problems in Younger Women After Breast Cancer SurgeryJournal of Clinical Oncology, 2006
- Eighteen‐year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapyCancer, 2003
- Twenty-Year Follow-up of a Randomized Study Comparing Breast-Conserving Surgery with Radical Mastectomy for Early Breast CancerThe New England Journal of Medicine, 2002
- Combined chemotherapy and radiotherapy for locally advanced breast cancerEuropean Journal of Cancer (1965), 1980